human cytotoxic t cell

Overview

Human cytotoxic T cells (CTLs), formally designated CD8⁺ T lymphocytes, are a critical effector population of the adaptive immune system responsible for the direct elimination of infected, transformed, or otherwise aberrant cells. They recognize peptide antigens presented on major histocompatibility complex class I (MHC-I) molecules, which are expressed on virtually all nucleated cells in the body. Upon antigen recognition, CTLs deploy a suite of cytotoxic mechanisms—including perforin-granzyme-mediated lysis, Fas/FasL-induced apoptosis, and the secretion of proinflammatory cytokines such as interferon-gamma and tumor necrosis factor-alpha—to destroy their targets. CTLs also form long-lived memory populations that provide durable immunological protection upon re-exposure to the same antigen. Their capacity to survey tissues and eliminate malignant cells makes them a central focus of modern cancer immunotherapy.

In the tumor microenvironment (TME), CD8⁺ T cells frequently encounter conditions that drive a hypo-functional state known as exhaustion, characterized by the progressive upregulation of inhibitory receptors—including programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4)—and a corresponding loss of effector function. This exhaustion program, shaped by chronic antigen exposure, metabolic stress, and suppressive signals from regulatory T cells, macrophages, and tumor cells, represents a primary barrier to effective antitumor immunity. Overcoming CD8⁺ T cell exhaustion has therefore become a central objective of therapeutic strategies involving checkpoint inhibitor and next-generation cancer vaccines.

Focus of Latest Publications

Recent publications have focused on human cytotoxic T cells, especially CD8+ T cells, as key effectors of antitumor and antiviral immunity and as readouts of immune dysfunction in disease. Several studies examined how these cells are recruited, activated, or suppressed within the tumor microenvironment or inflamed tissues, using approaches such as single-cell transcriptomics, proteomics, immunohistochemistry, spatial multi-omics, and co-culture systems. Across these reports, CD8+ T cell abundance, dysfunction, and killing capacity were linked to treatment response, immune escape, and therapeutic efficacy.

In colorectal cancer, an orthotopic organoid-based mouse model showed that CD8+ T cells were the predominant leukocyte population in tumor infiltrates and included populations transitioning toward dysfunction. Depletion of CD8+ T cells increased tumor burden, supporting their antitumor role, while anti-PD-1 treatment expanded dysfunctional CD8+ T cell populations and reduced tumor growth. Related vaccine studies also aimed to strengthen CD8+ T cell immunity: an mRNA nanovaccine fused to angiotensin II enhanced dendritic cell maturation and cDC1 abundance, leading to potent antigen-specific CD8+ T cell responses and tumor inhibition, and immunogenic cell death-primed autophagosome vaccines promoted cDC1 cross-presentation and robust CD8+ T cell responses with strong activity against colon cancer metastasis.

Other studies linked CD8+ T cell function to immunotherapy sensitivity or resistance in solid tumors. In esophageal squamous cell carcinoma, high mitochondrial complex I protein expression in tumor cells or patient-derived organoids increased sensitivity to CD8+ T cell-mediated killing and was associated with anti-PD-1 responsiveness, whereas YAP1 activation impaired immunotherapy efficacy. In hepatocellular carcinoma, SETDB2 deficiency enhanced CD8+ T cell infiltration and improved the immune microenvironment, while SETDB2 overexpression promoted immunosuppression and reduced effector T cell function. Another multi-omics study in liver cancer found that cholic acid enriched at the tumor margin induced CD8+ T cell dysfunction through NR1H4-dependent PD1 upregulation, and NR1H4 inhibition synergized with anti-PD-1 therapy.

Additional work explored strategies to increase CD8+ T cell infiltration and antitumor activity through immune checkpoint modulation and immunogenic cell death. A ratio-tunable nanoparticle platform targeting CD47 and PD-L1, combined with ultrasound-activated sonodynamic therapy, increased dendritic cell maturation, shifted macrophages toward an M1-like phenotype, and increased CD8+ T cell infiltration in syngeneic tumor models. In the CNS, an immunohistochemical cohort study in multiple sclerosis and natalizumab-associated progressive multifocal leukoencephalopathy investigated lymphoid infiltrates, including tissue-resident memory CD8+ T cells, to assess antiviral immunity and clinical outcomes. Together, these studies position human cytotoxic T cells as central targets for understanding immune dysfunction and for designing therapies that enhance antitumor and antiviral immunity.

Key Publications

NEWJun Brain Immune Cell Composition in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy After Natalizumab: An Immunohistochemical Cohort Study. (Neurology(R) neuroimmunology & neuroinflammation, 2026, PMID 42275616): "Tissue-resident memory CD8+ T cells (TRM CD8+), which rely on activation through CD4+ T cells, are essential for antiviral defense and may contribute to JC virus (JCV) control."
May An orthotopic organoid-based model to study early CD8⁺ T cell dysfunction and immunotherapy response in colorectal cancer. (Oncoimmunology, 2026, PMID 42141809): "A deeper understanding of CD8+ T cell exhaustion and its contribution to immune checkpoint inhibitor (ICI) responsiveness is essential for the development of more effective therapeutic strategies."
Apr An mRNA Tumor Nanovaccine Expressing Tumor Antigen Fused With Angiotensin II Facilitates Type 1 Conventional Dendritic Cell-Mediated Anti-Tumor Immunity. (Small (Weinheim an der Bergstrasse, Germany), 2026, PMID 42043950): "...to enhance the antigen presentation efficiency of mRNA-encoded tumor antigens and the intensity of vaccine-induced CD8+ T cell response remains a great challenge."
Apr Ratio-Tunable Dual-Peptide and Ultrasound-Assisted Nanoplatform for Enhancing Personalized Antitumor Immunotherapy. (Advanced materials (Deerfield Beach, Fla.), 2026, PMID 41979280): "ultrasound-activated BiNPs with a selected peptide ratio enhance dendritic cell maturation, shift macrophages toward an M1-like phenotype, increase CD8+ T cell infiltration, and suppress primary and distant tumors with favorable biosafety."
Apr Proteome profiles of esophageal squamous cell carcinoma tie mitochondrial complex I to immunotherapy. (EMBO molecular medicine, 2026, PMID 41965870): "High mitochondrial complex I protein expression of ESCC cells or patient-derived organoids increases sensitivity to CD8+ T cell-mediated killing in the co-culture systems."
Apr SETDB2 induces abnormal SHP-1 splicing and promotes immunosuppression in hepatocellular carcinoma. (Oncogene, 2026, PMID 41946995): "Functional experiments showed that SETDB2 deficiency could significantly inhibit tumorigenesis, enhance CD8+ T cell infiltration, and improve the immune microenvironment."
May Immunogenic cell death-primed autophagosome vaccines drive dendritic cell cross-presentation and suppress colon cancer metastasis. (Journal of controlled release : official journal of the Controlled Release Society, 2026, PMID 41856327): "...thereby priming CD8+ T cell immunity."
Apr Multi-omics profiling reveals cholic acid-mediated immunosuppression driven by peritumoral ductular reactions in hepatocellular carcinoma. (Cancer letters, 2026, PMID 41780844): "Metabolomic profiling revealed tumor margin enrichment of cholic acid, which induced CD8+ T cell dysfunction via NR1H4-dependent PD1 upregulation."